Fortress Biotech, Inc. (FBIO) 주식 분석

회사 개요

Fortress Biotech, Inc. (FBIO) operates as a biopharmaceutical company dedicated to the development and commercialization of specialized biopharmaceutical products, with a primary focus on the dermatology sector. The company markets specific therapeutic solutions such as Emrosi, an extended-release capsule formulation of minocycline hydrochloride designed for rosacea treatment, and Qbrexza, a medicated cloth intended for skin conditions. This entity functions within the broader Healthcare sector, specifically inside the Biotechnology industry, where innovation in drug discovery and clinical development drives value creation. The company currently maintains a market capitalization of $77.29M and generates annual revenue of $63.26M, while the number of employees is not publicly disclosed in available records. These valuation and revenue metrics suggest that Fortress Biotech, Inc. occupies a mid-cap position within the biotechnology landscape, reflecting a company that has achieved commercial product launch but remains in a phase of significant operational scaling and investment.

재무 건전성

Fortress Biotech, Inc. reported a revenue of $63.26M over the trailing twelve months, yet it recorded a net income of -$1,882,000 and an EBITDA of -$65,560,000. The substantial negative gap between revenue and net income reveals a cost structure characterized by high operating expenses, likely driven by research, development, and commercialization efforts typical for biotechnology firms. The company's free cash flow stands at -$47,286,376, indicating a significant cash outflow that limits immediate financial flexibility and necessitates reliance on existing cash reserves or external capital markets. In terms of profitability margins, the company demonstrates a gross margin of 48.1%, which suggests favorable pricing power or low cost of goods sold relative to sales, but this is offset by an operating margin of -29.8% and a profit margin of 10.8% that appears anomalous given the negative net income, potentially indicating accounting adjustments or specific financial instrument classifications in the reported data. The balance sheet shows a cash position of $79.38M against total debt of $67.22M, resulting in a debt-to-equity ratio of 108.09, which indicates a leveraged balance sheet where liabilities significantly outweigh equity. Despite the high leverage, the current ratio of 2.49 suggests that the company possesses strong short-term liquidity, as current assets are more than double current liabilities, providing a buffer against immediate payment obligations. Furthermore, the return on equity is -108.7% and the return on assets is -26.6%, metrics that reveal that management effectiveness is currently challenged by net losses that are eroding the book value of the company's equity and utilizing its asset base inefficiently in terms of profit generation.

밸류에이션 평가

The valuation metrics for Fortress Biotech, Inc. present a complex picture, with a trailing twelve-month P/E ratio listed as N/A due to losses, while the forward P/E is calculated at -1.36. The discrepancy between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing in a trajectory of continued negative earnings, making traditional earnings-based valuation methods inapplicable for the foreseeable future. The price-to-book ratio is 1.33, indicating that the market values the company at 1.33 times its book value, which suggests a premium over the net asset value likely derived from intangible assets, intellectual property, and pipeline potential rather than current earnings power. Alternative valuation metrics such as the price-to-sales ratio of 1.22 and an EV/EBITDA of -1.18 further suggest that investors are valuing the company based on revenue generation and enterprise value rather than profitability, highlighting the speculative nature of the investment. Regarding trading ranges, the 52-week high is $4.53 and the 52-week low is $1.33, providing a historical context for price volatility within the current fiscal year. The company's stock beta is 1.45, which means that the stock price is expected to be 45% more volatile than the broader market, amplifying both potential gains and losses during periods of market fluctuation.

Growth & Income

The company has achieved a revenue growth rate of 6.3% year-over-year, while earnings growth is marked as N/A due to the absence of positive earnings data. Since earnings are negative, they are not growing in the traditional sense of increasing profit, but rather the company is focusing on expanding its top line through product sales rather than immediate profitability. As a non-dividend payer, Fortress Biotech, Inc. does not distribute a dividend yield or maintain a payout ratio, as indicated by the 0.0% payout ratio, meaning the company reinvests all available cash flow and retained earnings into research, development, and commercial expansion rather than returning capital to shareholders. This growth-oriented strategy is consistent with early-to-mid stage biotechnology companies that prioritize building a product portfolio and market presence over shareholder distributions. The overall growth and income profile is defined by moderate revenue expansion coupled with significant cash burn and a lack of current income generation, relying entirely on the potential future value of its dermatology products and pipeline developments to drive future financial performance.